Effect of Semaglutide versus placebo on psychotic symptoms and quality of life - a pre-specified secondary analysis of HISTORI: A randomized clinical trial in people with pre-diabetes and schizophrenia
Introduction Life expectancy of people with schizophrenia is reduced by 10-20 years compared to the general population. The excess mortality is part due to an increased prevalence of cardiovascular disease, prediabetes and obesity, which are in part due to antipsychotic treatment. Gaining weight is...
Main Authors: | N. Uhrenholt, A. Ganeshalingam, S. Arnfred, J. Frystyk, P. Gæde, N. Bilenberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-06-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822020648/type/journal_article |
Similar Items
-
Evaluation of the Effect of Alkaloid Berberine on the Positive and Negative Symptoms of the Patients with Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial
by: Ebrahim Moghimi Sarani, et al.
Published: (2022-09-01) -
Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
by: Somaye Arabzadeh, et al.
Published: (2018-02-01) -
Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial
by: Peter Haulund Gæde, et al.
Published: (2024-03-01) -
Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia
by: Agnieszka Markiewicz-Gospodarek, et al.
Published: (2022-06-01) -
Prevalence of depression in persons with schizophrenia – A cross-sectional study from a tertiary psychiatric hospital
by: Reshma Susan Mathew, et al.
Published: (2023-06-01)